Significant Revenue Growth
Revenue from continuing operations was $11.8 million, an increase of 59% over the prior-year period. This growth was driven by device sales, with mass spec devices accounting for roughly 60% of revenue and FTIR products making up the other 40%.
Recurring Revenue Increase
Recurring revenue increased 54% from the previous year and represented 37% of total revenues.
Improved Adjusted EBITDA
Adjusted EBITDA loss improved nearly 50% year-over-year in Q1 2025 compared to Q1 2024.
Strategic Orders and Partnerships
Secured a $2 million order from the Texas Department of Public Safety and additional orders from the Washington Metro Area Transit Authority and Homeland Security Investigations, indicating strong demand and expanding market presence.
Successful Integration of RedWave Technology
The acquisition of RedWave Technology has diversified the product portfolio and contributed significantly to revenue, with FTIR products accounting for 40% of Q1 revenue.
Strong Cash Position
The company ended the first quarter with $124.3 million in cash, cash equivalents, and marketable securities, supported by the $70 million cash sale of the bioprocessing portfolio.